Daniel E. Meyers

937 total citations · 1 hit paper
41 papers, 618 citations indexed

About

Daniel E. Meyers is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Daniel E. Meyers has authored 41 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Economics and Econometrics. Recurrent topics in Daniel E. Meyers's work include Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (13 papers) and CAR-T cell therapy research (9 papers). Daniel E. Meyers is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (13 papers) and CAR-T cell therapy research (9 papers). Daniel E. Meyers collaborates with scholars based in Canada, United States and United Kingdom. Daniel E. Meyers's co-authors include Don Morris, Shantanu Banerji, Igor Stukalin, Aliyah Pabani, Tina Cheng, Chandini M. Thirukkumaran, Kristina Jenei, Bishal Gyawali, Vishal Navani and Daniel Yick Chin Heng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Daniel E. Meyers

38 papers receiving 614 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel E. Meyers Canada	15	412	179	108	86	70	41	618
Navdeep Pal United States	11	189 0.5×	127 0.7×	91 0.8×	45 0.5×	47 0.7×	26	689
Timothée Olivier Switzerland	15	463 1.1×	341 1.9×	123 1.1×	65 0.8×	34 0.5×	83	873
Eucario León-Rodrı́guez Mexico	13	284 0.7×	108 0.6×	132 1.2×	95 1.1×	36 0.5×	47	641
Meredith K. Chuk United States	14	429 1.0×	260 1.5×	175 1.6×	133 1.5×	41 0.6×	29	858
Federico Rotolo France	14	296 0.7×	207 1.2×	167 1.5×	146 1.7×	29 0.4×	32	781
Kelsey L. Corrigan United States	12	296 0.7×	97 0.5×	93 0.9×	154 1.8×	22 0.3×	52	585
Claudio Flores Peru	11	278 0.7×	136 0.8×	85 0.8×	101 1.2×	32 0.5×	41	493
Rosa Giuliani Italy	15	524 1.3×	128 0.7×	166 1.5×	127 1.5×	44 0.6×	31	805
Damir Vrbanec Croatia	14	269 0.7×	69 0.4×	129 1.2×	91 1.1×	41 0.6×	45	486
Bryan A. Faller United States	11	325 0.8×	179 1.0×	196 1.8×	47 0.5×	27 0.4×	32	532

Countries citing papers authored by Daniel E. Meyers

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Meyers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Meyers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Meyers more than expected).

Fields of papers citing papers by Daniel E. Meyers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Meyers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Meyers. The network helps show where Daniel E. Meyers may publish in the future.

Co-authorship network of co-authors of Daniel E. Meyers

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Meyers. A scholar is included among the top collaborators of Daniel E. Meyers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Meyers. Daniel E. Meyers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meyers, Daniel E., et al.. (2024). Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials. Current Oncology. 31(9). 5498–5515.

Cook, Sarah, Daniel E. Meyers, Igor Stukalin, et al.. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 7(1). e2352302–e2352302. 60 indexed citations breakdown →

Stukalin, Igor, et al.. (2024). Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study. Frontiers in Oncology. 14. 1385425–1385425.

Meyers, Daniel E., Igor Stukalin, Shannon Puloski, et al.. (2024). Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer. Frontiers in Immunology. 15. 1379056–1379056. 6 indexed citations

Navani, Vishal, Daniel E. Meyers, Yibing Ruan, et al.. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. Clinical Lung Cancer. 24(3). e152–e159. 2 indexed citations

Stukalin, Igor, Vishal Navani, Yibing Ruan, et al.. (2023). Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. The Oncologist. 28(9). 812–822. 6 indexed citations

Stukalin, Igor, Daniel E. Meyers, Daniel Y.C. Heng, et al.. (2023). Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma. JAMA Network Open. 6(6). e2319607–e2319607. 6 indexed citations

Meyers, Daniel E., Igor Stukalin, Vishal Navani, et al.. (2023). Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 4(4). 100482–100482. 14 indexed citations

Banerji, Shantanu, Daniel E. Meyers, Craig Harlos, & David E. Dawe. (2021). The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma. Current Oncology. 28(6). 4542–4551. 4 indexed citations

10.

Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations

11.

Gibson, Adam, Daniel E. Meyers, Michael Dean, et al.. (2021). P16.03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients. Journal of Thoracic Oncology. 16(3). S348–S348.

12.

Jenei, Kristina, Adam Raymakers, Daniel E. Meyers, & Vinay Prasad. (2021). Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015–2020. Journal of Cancer Policy. 30. 100311–100311. 3 indexed citations

13.

Meyers, Daniel E., Kristin Wright, Bishal Gyawali, et al.. (2021). Temporal trends in oncology drug revenue among the world’s major pharmaceutical companies: A 2010-2019 cohort study.. Journal of Clinical Oncology. 39(15_suppl). 6505–6505. 1 indexed citations

14.

Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations

15.

Lewinson, Ryan T., Daniel E. Meyers, Isabelle A. Vallerand, et al.. (2020). Machine learning for prediction of cutaneous adverse events in patients receiving anti–PD-1 immunotherapy. Journal of the American Academy of Dermatology. 84(1). 183–185. 14 indexed citations

16.

Meyers, Daniel E. & Shantanu Banerji. (2020). Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Current Oncology. 27(12). 106–114. 19 indexed citations

17.

Yip, Steven, Daniel E. Meyers, Jeff Sisler, et al.. (2020). Oncology education for family medicine residents: a national needs assessment survey. BMC Medical Education. 20(1). 283–283. 9 indexed citations

18.

Mostafa, Ahmed, Daniel E. Meyers, Chandini M. Thirukkumaran, et al.. (2018). Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer. Cancers. 10(6). 205–205. 43 indexed citations

19.

Meyers, Daniel E., Satbir Thakur, Chandini M. Thirukkumaran, & Don Morris. (2017). Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Blood Cancer Journal. 7(12). 640–640. 20 indexed citations

20.

Meyers, Daniel E., Ángela María Segura Cardona, L. Maximilian Buja, et al.. (2013). Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis. American Journal of Transplantation. 13(10). 2730–2733. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact